TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04654312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Please see arm descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Please see arm descriptions
Study: NCT05600127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 3 cycles of avelumab (800mg, every 2 weeks)
Study: NCT04473807

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation
Description: The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
Study: NCT05239754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Services
Description: Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
Study: NCT05684276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study: NCT06391190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel, cisplatin, Sintilimab
Description: with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
Study: NCT06221527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
Study: NCT05772351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized flavonoid fraction
Description: Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work.
Study: NCT05841173

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PanTrek
Description: The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PanTrek
Description: The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Trainings
Description: Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
Study: NCT05564338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally
Study: NCT04800757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual -Brief Motivational Intervention (BMI)
Description: A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group (Group Problem Solving)
Description: Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (OSHA 10 Safety Cards)
Description: Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
Study: NCT05564338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib-matching placebo
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib-matching placebo
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab-matching placebo
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab-matching placebo
Description: administered intravenously
Study: NCT06080672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)
Description: All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)
Description: All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
Study: NCT06217250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional EMR
Description: Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms
Description: The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR.
Study: NCT06231017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Cetuximab+ Chemotherapy
Description: Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
Study: NCT05987215

Intervention type: COMBINATION_PRODUCT
Intervention: Radiologic diagnosis
Description: Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis

Intervention type: COMBINATION_PRODUCT
Intervention: Radiologic diagnosis
Description: Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence diagnosis
Description: Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence diagnosis
Description: Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
Study: NCT05657262

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-post test
Description: Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-post test
Description: Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The experiment group will be applied with the Z technique.
Study: NCT04810273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early progressive mobilization
Description: The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early progressive mobilization
Description: The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
Study: NCT05025943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
Study: NCT04970329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Description: Drugs will be given to two group and third group will kept on placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Description: Drugs will be given to two group and third group will kept on placebo.
Study: NCT05898997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
Study: NCT06131437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide will be administered subcutaneously.
Study: NCT04782232

Intervention type: OTHER
Intervention: No intervention
Description: No intervention due to observational design
Study: NCT04789213

Intervention type: OTHER
Intervention: Liver Transplantation
Description: Liver Transplantation

Intervention type: OTHER
Intervention: Liver Transplantation
Description: Liver Transplantation
Study: NCT04925154

Intervention type: BEHAVIORAL
Intervention: The only intervention will be the information brochure that will be given after the first questionnaire.
Description: The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).

Intervention type: BEHAVIORAL
Intervention: The only intervention will be the information brochure that will be given after the first questionnaire.
Description: The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
Study: NCT04910308

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided dose painting
Description: The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
Study: NCT04839562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 MG
Description: Daily oral consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 MG
Description: Daily oral consumption

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06038812

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GCF sample collection
Description: collecting GCF from deepest sites by paper points
Study: NCT04970329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
Description: Drugs will be given to two group and third group will kept on placebo.
Study: NCT05461378

Intervention type: DRUG
Intervention: Evusheld
Description: Participants who have received or plan to receive Evusheld.

Intervention type: DRUG
Intervention: Evusheld
Description: Participants who have received or plan to receive Evusheld.

Intervention type: DRUG
Intervention: Evusheld
Description: Participants who have received or plan to receive Evusheld.